{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:20:42Z","timestamp":1788970842331,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jcf.2025.10.006","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T16:23:24Z","timestamp":1760804604000},"page":"70-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass index"],"prefix":"10.1016","volume":"25","author":[{"given":"Andrew","family":"Horvit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9829-7556","authenticated-orcid":false,"given":"Katie","family":"Kaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6429-2479","authenticated-orcid":false,"given":"Amber","family":"Neece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0391-7207","authenticated-orcid":false,"given":"Jessica","family":"Abramowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-0661","authenticated-orcid":false,"given":"Marconi","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5833-3532","authenticated-orcid":false,"given":"James D.","family":"Finklea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-5737","authenticated-orcid":false,"given":"Sasan","family":"Mirfakhraee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2025.10.006_bib0001","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ccm.2015.11.009","article-title":"Nutritional issues in Cystic Fibrosis","volume":"37","author":"Solomon","year":"2016","journal-title":"Clin Chest Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.10.006_bib0002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1569-1993(02)00076-0","article-title":"Resting energy expenditure and lung disease in cystic fibrosis","volume":"1","author":"Dorlochter","year":"2002","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.10.006_bib0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/0884533613507086","article-title":"Malnutrition in cystic fibrosis: a review","volume":"28","author":"Culhane","year":"2013","journal-title":"Nutr Clin Pract"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.006_bib0004","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","article-title":"Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis","volume":"19","author":"Harindhanavudhi","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2025.10.006_bib0005","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors","volume":"39","author":"Bonhoure","year":"2020","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1016\/j.jcf.2025.10.006_bib0006","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3945\/ajcn.112.051409","article-title":"Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study","volume":"97","author":"Stephenson","year":"2013","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.jcf.2025.10.006_bib0007","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"issue":"3","key":"10.1016\/j.jcf.2025.10.006_bib0008","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jcf.2025.10.006_bib0009","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"issue":"19","key":"10.1016\/j.jcf.2025.10.006_bib0010","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jcf.2025.10.006_bib0011","first-page":"16","article-title":"Is obesity a problem in new Cystic fibrosis treatments?","author":"Solis-Garcia","year":"2024","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.jcf.2025.10.006_bib0012","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.006_bib0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jcf.2024.09.022","article-title":"Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Ratti","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2025.10.006_bib0014","first-page":"105","article-title":"Semaglutide in cystic fibrosis-related diabetes","author":"Gnanapragasam","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.006_bib0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jcf.2024.08.005","article-title":"Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis","volume":"24","author":"Park","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.006_bib0016","article-title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review","volume":"38","author":"Ahmed","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"10.1016\/j.jcf.2025.10.006_bib0017","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/dia.2024.0367","article-title":"GLP-1 receptor agonist therapy in cystic fibrosis-related diabetes: A case report","volume":"27","author":"Ayada","year":"2025","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"10.1016\/j.jcf.2025.10.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of body mass index with clinical outcomes in patients with Cystic fibrosis: A systematic review and meta-analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jcf.2025.10.006_bib0019","article-title":"Obesity in cystic fibrosis","volume":"26","author":"Kutney","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"issue":"8","key":"10.1016\/j.jcf.2025.10.006_bib0020","first-page":"860","article-title":"Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy","volume":"90","author":"Rolon","year":"2001","journal-title":"Acta Paediatr"},{"issue":"3","key":"10.1016\/j.jcf.2025.10.006_bib0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-5448.2008.00451.x","article-title":"One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements","volume":"10","author":"Mozzillo","year":"2009","journal-title":"Pediatr Diabetes"},{"issue":"8","key":"10.1016\/j.jcf.2025.10.006_bib0022","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1651-2227.1994.tb13156.x","article-title":"Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections","volume":"83","author":"Lanng","year":"1994","journal-title":"Acta Paediatr"},{"issue":"5","key":"10.1016\/j.jcf.2025.10.006_bib0023","article-title":"Positive impact of insulin treatment on clinical trend in cystic fibrosis patients: a retrospective study","volume":"93","author":"Giugno","year":"2022","journal-title":"Acta Biomed"},{"issue":"1","key":"10.1016\/j.jcf.2025.10.006_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1513\/AnnalsATS.202212-1026OC","article-title":"Effects of weight change and weight cycling on lung function in overweight and obese adults","volume":"21","author":"De Soomer","year":"2024","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"10.1016\/j.jcf.2025.10.006_bib0025","first-page":"60","article-title":"Potential use of GLP-1 and GIP\/GLP-1 receptor agonists for respiratory disorders: where are we at?","author":"Janic","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"10.1016\/j.jcf.2025.10.006_bib0026","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting","volume":"48","author":"Korner","year":"2007","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.10.006_bib0027","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1210\/endo.139.5.5998","article-title":"Glucagon-like peptide-1-(7-36)amide increases pulmonary surfactant secretion through a cyclic adenosine 3\u2032,5\u2032-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes","volume":"139","author":"Benito","year":"1998","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.jcf.2025.10.006_bib0028","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.jcf.2025.10.006_bib0029","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1210\/en.2013-1666","article-title":"Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice","volume":"154","author":"Viby","year":"2013","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.jcf.2025.10.006_bib0030","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1136\/thorax-2023-221040","article-title":"Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD","volume":"79","author":"Yen","year":"2024","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.jcf.2025.10.006_bib0031","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2025.10.006_bib0032","article-title":"Body composition in individuals with cystic fibrosis","volume":"26","author":"Soltman","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"issue":"4","key":"10.1016\/j.jcf.2025.10.006_bib0033","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jcf.2021.05.016","article-title":"Review of gastrointestinal motility in Cystic fibrosis","volume":"20","author":"Henen","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325024907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325024907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:57:17Z","timestamp":1772891837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325024907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1569199325024907"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.10.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass index","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}